Shuttle Pharma gets positive FDA feedback for Ropidoxuridine Phase 2; cash $6.8M

Shuttle Pharmaceuticals Holdings, Inc.

Positive FDA feedback in Type B PIND meeting for Ropidoxuridine; IND submission imminent to start Phase 2 trial for glioblastoma.
Exclusive license from Georgetown University for predictive biomarker test for prostate cancer radiation therapy.
Q3 2023 operating expenses (excl non-cash) $1.6M; cash, cash equivalents and marketable securities $6.8M at Sep 30, 2023.
Expanded patent coverage on HDAC inhibitor platform; published manuscript on SP-2-225 immune response post-radiation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.6

Shuttle Pharmaceuticals Holdings, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

issued a press release providing a corporate update in connection with the filing of our quarterly report on Form 10-Q for the period ended September 30, 2023.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040810

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.